The following is a review to revisit the application and utility of BSO in the context of adjuvant endocrine suppression including selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs), and to highlight the long-term sequelae of BSO among individuals with premenopausal ER+ breast cancer. The gene discussed is CYP19A1; the disease is breast cancer.